-
公开(公告)号：US20240226261A9
公开(公告)日：2024-07-11
申请号：US18386593
申请日：2023-11-02
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Elisabeth Marie Monique BERTAUD , Ralph Leon BIEMANS , Nicolas Jean Benoit MONIOTTE , Laurent Bernard Jean STRODIOT
CPC classification number: A61K39/092 , A61K47/6415 , A61K47/646 , A61K2039/6087
Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.
-
公开(公告)号：US20180303923A1
公开(公告)日：2018-10-25
申请号：US15769542
申请日：2016-10-19
Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
Inventor： Elisabeth Marie Monique BERTAUD , Ralph Leon BIEMANS , Nicolas Jean Benoit MONIOTTE , Laurent Bernard Jean STRODIOT
CPC classification number: A61K39/092 , A61K47/6415 , A61K47/646 , A61K2039/6087 , A61K2039/62 , A61K2039/70
Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.
-
Patent Agency Ranking
公开(公告)号：US20220354941A1
公开(公告)日：2022-11-10
申请号：US17854377
申请日：2022-06-30
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Ralph Leon BIEMANS , Nathalie Marie-Josephe GARCON , Philippe Vincent HERMAND , Jan POOLMAN , Marcelle Paulette VAN MECHELEN
IPC: A61K39/09 , A61K39/385 , A61K47/64 , A61K47/61
Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition for infants is provided comprising a multivalent Streptococcus pneumoniae vaccine comprising 2 or more capsular saccharide conjugates from different serotypes, wherein the composition comprises a serotype 22F saccharide conjugate. Such a vaccine may be used in infant populations to reduce the incidence of elderly pneumococcal disease such as exacerbations of COPD and/or IPD.
-
公开(公告)号：US20220211859A1
公开(公告)日：2022-07-07
申请号：US17608230
申请日：2020-05-07
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Ralph Leon BIEMANS , Elisabeth Marie Monique BERTAUD
Abstract: This application relates to methods for the production of polysaccharide antigen-carrier protein conjugates, in particular conjugates of Group B Streptococcus (GBS) capsular polysaccharide and a carrier protein, in particular CRM197. The methods comprise a hydroxyapatite chromatography step in order to separate the conjugate from free polysaccharide and free carrier protein.
-
公开(公告)号：US20240131136A1
公开(公告)日：2024-04-25
申请号：US18386593
申请日：2023-11-01
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Elisabeth Marie Monique BERTAUD , Ralph Leon BIEMANS , Nicolas Jean Benoit MONIOTTE , Laurent Bernard Jean STRODIOT
CPC classification number: A61K39/092 , A61K47/6415 , A61K47/646 , A61K2039/6087
Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.
-
公开(公告)号：US20180104322A1
公开(公告)日：2018-04-19
申请号：US15832240
申请日：2017-12-05
Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
Inventor： Ralph Leon BIEMANS , Dominique BOUTRIAU , Philippe Thomas DENOEL , Pierre DUVIVIER , Carine GORAJ
IPC: A61K39/085 , A61K39/00
CPC classification number: A61K39/085 , A61K47/6415 , A61K47/646 , A61K2039/545 , A61K2039/55566 , A61K2039/57 , A61K2039/6037 , A61K2039/6068 , A61K2039/70
Abstract: This application relates to immunogenic compositions comprising a Staphylococcus aureus Type 5 capsular saccharide conjugated to a carrier protein to form a S. aureus Type 5 capsular saccharide conjugate.
-
公开(公告)号：US20170281744A1
公开(公告)日：2017-10-05
申请号：US15529094
申请日：2015-12-08
Applicant: GlaxoSmithKline Biologicals SA
Inventor： Ralph Leon BIEMANS , Dominique BOUTRIAU , Philippe DENOEL , Pierre DUVIVIER , Carine GORAJ
IPC: A61K39/085 , A61K45/06 , C07K14/31
CPC classification number: A61K39/085 , A61K39/00 , A61K45/06 , A61K2039/555 , A61K2039/58 , A61K2039/6037 , A61K2039/70 , C07K14/31 , C07K2319/00
Abstract: The application discloses a method of immunising against Staphylococcus aureus infection comprising a step of administering to a human patient a single dose of an immunogenic composition comprising; (i) a Staphylococcus aureus ClfA protein or immunogenic fragment thereof at a dose of 5-50, 10-30, 5-15 or 20-40 μg and (ii) a pharmaceutically acceptable excipient; wherein the pH of the composition is pH 5.0-pH 8.0. The application further discloses an immunogenic composition comprising; (i) a S. aureus Type 5 capsular saccharide conjugated to a carrier protein, (ii) a S. aureus Type 8 capsular saccharide conjugated to a carrier protein, (iii) a ClfA protein or immunogenic fragment thereof, (iv) an alpha toxoid, and (v) a pharmaceutically acceptable excipient; wherein the pH of the immunogenic composition is pH 5.0-pH 8.0
-
-
-
-
-
-
Search Results
7
records
(took 0.015 seconds)
